Cargando…
Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) >100 mg/daily. This restriction is based on the hypothesis that ASA doses >100 mg somehow decreased ticagrelor’s benefit in the Platelet Inh...
Autores principales: | DiNicolantonio, James J., Serebruany, Victor L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581224/ https://www.ncbi.nlm.nih.gov/pubmed/23431005 http://dx.doi.org/10.2337/db12-0746 |
Ejemplares similares
-
Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021) -
The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
por: Fornaro, Michele, et al.
Publicado: (2019) -
855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals
por: Yarrington, Michael, et al.
Publicado: (2018) -
Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022) -
Unpacking the black box of improvement
por: Ramaswamy, Rohit, et al.
Publicado: (2018)